logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
IDYA
IDEAYA Biosciences, Inc.
36.17
2 x 26.62
2 x 46.27
bid
ask
-
1.10
2.95%
2 @ 04:00 PM
36.00 -0.17 (0.47%)
Ytd4.63%
1y71.26%
35.78
day range
37.63
20.96
52 week range
39.28
Open37.57Prev Close37.27Low35.78High37.63Mkt Cap3.48B
Vol1.25MAvg Vol1.38MEPS-1.57P/EN/AForward P/E-9.89
Beta-0.05Short Ratio9.74Inst. Own101.81%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-0550-d Avg30.32200-d Avg31.661yr Est52.79

IDYA News

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., June 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA),

benzinga.com
Ideaya Biosciences Enrolls First Patient In Its Phase 1 Trial Of IDE892 In Combination With IDE397

IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS
benzinga.com
Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price Target

Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and

Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
benzinga.com
Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks M

U.S. stock futures higher, Nasdaq up 200 points. Mission Produce (NASDAQ: AVO) shares down on weak e

Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket

GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT

12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
IDEAYA Biosciences Plans To Commence $300M Common Stock Offering

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) today announced that it intends to offer and sell up to $300.
benzinga.com
IDEAYA Enters Collaboration With Roche To Evaluate The Efficacy And Safety Of IDE892, Its Investigat

IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential b
benzinga.com
Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price Target

Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and
benzinga.com
IDEAYA Biosciences And Servier Presented Complete Data From Primary Analysis Of Phase 2/3 OptimUM-02

Key Findings from OptimUM-02Primary endpoint (Phase 2 portion): progression free survival by BICRThe